Halozyme Therapeutics Financials

Values in thousands	2026-06-30	2026-03-31	2025-12-31	2025-09-30
Revenue	$480,999	$376,708	$451,767	$354,264
Gross Profit	401,828	297,470	372,997	299,022
EBITDA	324,457	219,568	-69,258	243,674
EBIT	290,490	185,835	-95,938	223,254
Net Income	229,913	150,049	-141,591	175,225
Net Change In Cash	480,999	376,708	451,767	354,264
Free Cash Flow	236,718	176,337	217,602	175,567
Cash	163,138	309,749	133,820	419,665
Basic Shares	121,215	122,875	117,672	122,331

Values in thousands	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue	$1,396,611	$1,015,324	$829,253	$660,116
Gross Profit	1,167,837	855,907	636,892	520,812
EBITDA	573,052	656,539	451,947	315,506
EBIT	485,001	575,227	367,091	265,865
Net Income	316,889	444,091	281,594	202,129
Net Change In Cash	1,396,611	1,015,324	829,253	660,116
Cost of Revenue				115,476
Free Cash Flow	644,588	468,368	373,277	235,300
Cash	133,820	115,850	118,370	234,195
Basic Shares	123,904	129,424	134,197	140,608